

Regd. Office: Nirmala Apartments, 93, Jayprakash Road, Andheri (West), P.O. Box. 37396, Mumbai - 400 058. Phone: 3075 7575 (30 Lines)

Fax: 91-22-6694 3127 e-mail: info@jenburkt.com website: www.jenburkt.com

## UNAUDITED FINANCIAL RESULTS FOR THE 1st QUARTER ENDED ON 30th JUNE, 2011.

## Rs. in lacs

Sr. No.		Quarter ended	Quarter ended	Accounting year ended on
	Particulars	30/06/11	30/06/10	31/03/2011
		Unaudited	Unaudited	Audited
1	Net Sales / Income from Operations	1244.39	1281.00	5642.46
2	Expenditures:			
a)	(increase) or decrease in Stock	74.71	103.19	(32.39)
b)	Consumption of raw materials	367.09	372.22	2126.10
c)	Trade Purchase	0.24	6.69	75.49
d)	Employees Cost	288.46	323.43	1138.72
e)	Depreciation	24.00	21.00	98.30
f)	Other Expenditure:			
	Selling & Distribution Cost	275.19	198.63	1004.60
	Administration Cost	70.47	69.74	304.47
	R & D Expenses	9.99	7.15	57.53
	Total Expenditures	1110.15	1102.05	4772.82
3	Profit from operations before other income, Interest and exceptional items (1-2)	134.24	178.95	869.64
4	Other Income	4.94	1.07	91.46
5	Profit before interest and exceptional item (3+4)	139.18	180.02	961.10
6	Interest	12.14	7.62	52.13
7	Profit after Interest but before exceptional items (5-6)	127.04	172.40	908.97
8	Exceptional Items	-	-	-
9	Profit before tax (7+8)	127.04	172.40	908.97
10	Tax Expense	35.00	40.00	307.45
11	Net Profit after Tax (9-10)	92.04	132.40	601.52
12	Extra Ordinary Items (Net of tax expense)	-	-	-
13	Net Profit for the period (11-12)	92.04	132.40	601.52
14	Paid-up Equity Share Capital (face value of Rs.10/-each.)	464.93	464.93	464.93
15	Reserves and surplus	-	-	990.95
16	Earnings per share (EPS)			
	a) EPS before extra ordinary items for the period Basic & Diluted	1.98	2.85	12.94
	b) EPS after extra ordinary items for the	1.98	2.85	12.94
17	period Basic & Diluted	1.70	2.00	
17	Public shareholding : Number of Shares	2582252	2640634	2591939
	Percentage of Shareholding	55.54%	56.80%	55.75%





## Jenburkt Pharmaceuticals Ltd.

Regd. Office: Nirmala Apartments, 93, Jayprakash Road, Andheri (West), P.O. Box. 37396, Mumbai - 400 058, Phone: 3075 7575 (30 Lines)

18 Promoters & promoter group shareholding a) kt.com	website: www	.jenburkt.com	
pledged/encumbered			
No. of shares	Nil	Nil	Nil
% of the total shareholding of Promoter			
% of the total share capital of the co.			
b) Non-encumbered			
No. of shares	2067048	2008666	2057361
% of the total shareholding of Promoter	100.00%	100.00%	100.00%
% of the total share capital of the co.	44.46%	43.20%	44.25%

## Notes:

- 1. The above unaudited results were reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meetings held on 29<sup>th</sup> July, 2011.
- 2. The Company has been honoured by ICWAI, ranked "FIRST" for the prestigious "National Award for Excellence in Cost Management-2010". The award was presented by the honourable Union Minister of Corporate Affairs Dr. M. Veerappa Moily, on 18<sup>th</sup> July, 2011 at an award ceremony held at Vigyan Bhawan, New Delhi.
- 3. The Company has received prestigious rating for the fourth year in succession, from NSIC-CRISIL. The rating of "NSIC-CRISIL SE-1A" indicates "Highest performance capability and High financial strength".
- 4. Figures of previous quarter/year are regrouped/ rearranged, wherever necessary.
- 5. The Company is dealing exclusively in pharmaceuticals formulation business segment, hence segment wise presentation of financial result is not required.
- 6. The number of complaints received from shareholders during the quarter: Opening Balance=Nil, Complaints Received=1, Resolved=1, Pending = Nil.

For Jenburkt Pharmaceuticals Ltd.

(Uttam N. Bhuta)

Chairman and Managing Director.

Place : Mumbai Date : 29/07/2011.